×
Eliem Therapeutics Price to Free Cash Flow Ratio 2021-2024 | ELYM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Eliem Therapeutics price to free cash flow ratio from 2021 to 2024. Price to free cash flow ratio can be defined as
View More
Eliem Therapeutics Price to Free Cash Flow Ratio 2021-2024 | ELYM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Eliem Therapeutics price to free cash flow ratio from 2021 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$89B
Takeda Pharmaceutical (TAK)
$47.2B
Merck (MKGAF)
$23.7B
Astellas Pharma (ALPMY)
$22.1B
Summit Therapeutics (SMMT)
$17.8B
Sandoz Group AG (SDZNY)
$17.6B
United Therapeutics (UTHR)
$15.2B
Shionogi (SGIOY)
$13.1B
Neurocrine Biosciences (NBIX)
$12.1B
Catalent (CTLT)
$10.9B
Orion OYJ (ORINY)
$7.4B
Revolution Medicines (RVMD)
$7.4B
Jazz Pharmaceuticals (JAZZ)
$6.8B
Ionis Pharmaceuticals (IONS)
$6.2B
Hikma Pharmaceuticals Plc (HKMPF)
$5.7B
Madrigal Pharmaceuticals (MDGL)
$5.1B
Corcept Therapeutics (CORT)
$4.4B
Crinetics Pharmaceuticals (CRNX)
$4.2B
Dyne Therapeutics (DYN)
$3.4B
PTC Therapeutics (PTCT)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.4B
Soleno Therapeutics (SLNO)
$2.1B
Recursion Pharmaceuticals (RXRX)
$1.9B
Centessa Pharmaceuticals (CNTA)
$1.8B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Xencor (XNCR)
$1.6B
Harrow (HROW)
$1.6B
Cassava Sciences (SAVA)
$1.5B